{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > DNA Damage & DNA Repai > IrinotecanCAS：97682-44-5
Molecular Formula：C33H38N4O6
Molecular Weight：586.68
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥98%
Appearance：Light yellow to yellow Solid
Qty：
Size：
| CAS | 97682-44-5 |
| Name | Irinotecan |
| Molecular Formula | C33H38N4O6 |
| Molecular Weight | 586.68 |
| Solubility | Soluble in DMSO ≥10mg/mL |
| Purity | HPLC≥98% |
| Appearance | Light yellow to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 691-567-9 |
| MDL | MFCD01862255 |
| SMILES | O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3 |
| InChIKey | UWKQSNNFCGGAFS-XIFFEERXSA-N |
| InChI | InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1 |
| PubChem CID | 60838 |
| Target Point | Topoisomerase |
| Passage | DNA Damage/DNA Repair |
| Background | Irinotecan is a topoisomerase I inhibitor that prevents religation of DNA strands by binding to the topoisomerase I-DNA complex. |
| Biological Activity | Irinotecan是水溶性的拓扑异构酶I抑制剂，通过与拓扑异构酶I-DNA复合物结合来防止DNA链的再连接。[1-5] |
| In Vitro | 伊立替康是拓扑异构酶I抑制剂。伊立替康抑制LoVo和HT-29细胞的生长，IC50分别为15.8±5.1和5.17±1.4μM，并且在LoVo和HT-29细胞中诱导相似量的可切割复合物[2]。伊立替康抑制人脐静脉内皮细胞(HUVEC)的增殖，IC50为1.3μM[3]。 |
| In Vivo | 伊立替康(CPT-11，5mg / kg)在大鼠中连续两周每天通过肿瘤内注射显着抑制肿瘤的生长，并且这种效果也通过渗透微型泵连续腹膜内输注进入小鼠而发生。然而，伊立替康(10 mg / kg)对ip的生长没有影响[1]。伊立替康(CPT-11，100-300mg / kg，ip)显然在第21天抑制无胸腺雌性小鼠中HT-29异种移植物的肿瘤生长。两组伊立替康(125mg / kg)加TSP-1(10mg)/ kg /天或伊立替康(150 mg / kg)联合使用TSP-1(每天20 mg / kg)几乎同样有效，分别抑制肿瘤生长84％和89％，两者均比单独使用伊立替康更有效剂量为250和300毫克/千克[3]。 |
| Cell Experiment | 将指数生长的细胞接种在20cm 2培养皿中，每个细胞系具有最佳细胞数(对于LoVo细胞为20，000，对于HT-29细胞为100，000)。 2天后，用增加浓度的伊立替康或SN-38处理它们一个细胞倍增时间(LoVo细胞24小时，HT-29细胞40小时)。用0.15M NaCl洗涤后，细胞在正常培养基中进一步生长两次，用胰蛋白酶-EDTA从支持物上分离，并在血细胞计数器中计数。然后将IC50值估计为与不用药物孵育的细胞相比，负责50％生长抑制的药物浓度[2]。 |
| Animal Experiment | 伊立替康通过瘤内注射0.1cc体积的适当溶液给药，连续两周每天5mg / kg，连续两周，然后休息7天，称为一个治疗周期。大鼠在8周的时间内接受三个周期。对照动物通过瘤内注射以与第II组动物相同的给药规则接受0.1cc无菌0.9％氯化钠溶液[1]。 |
| Data Literature Source | [1]. Morales C， et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb; 56 (3) :219-26. [2]. Pavillard V， et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr; 49 (4) :329-35. Epub 2002 Jan 30. [3]. Allegrini G， et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar; 53 (3) :261-6. Epub 2003 Dec 5. [4]. Dela Cruz FS， et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31; 8 (1) :116. [5]. Huang MY， et al. Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. Apoptosis. 2016 Feb; 21 (2) :130-42. |
| Unit | Bottle |
| Specification | 10mg 10mM*1mL in DMSO 50mg |
Irinotecan是拓扑异构酶I抑制剂，通过与拓扑异构酶I-DNA复合物结合来防止DNA链的再连接。
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
